Michael A. Panzara - 25 Jul 2022 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Reporting relationship: Chief Medical Officer, Head of Therapeutics Discovery and Development
Issuer ticker: WVE
Reported as of: 25 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jul 2022, 21:05:15 UTC
Prior SEC filing: 27 May 2022
Next SEC filing: 22 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Panzara

Key filing fact

Michael A. Panzara filed Form 4 for Wave Life Sciences Ltd. (WVE) on 27 Jul 2022.

Key facts

This page summarizes Michael A. Panzara's Form 4 filing for Wave Life Sciences Ltd. (WVE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jul 2022, 21:05.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WVE transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024.

SEC remarks

Chief Medical Officer, Head of Therapeutics Discovery and Development